Shots:

• The US FDA has granted FT designation to APD418- currently in development for the treatment of DHF
•  The FDA’s Fast Track designation facilitate the development and expedite the review of therapy to treat serious conditions and fill an unmet medical need
• APD418 is a first-in-class β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope- designed to improve cardiac contractility with minimal effect on HR- BP & myocardial oxygen consumption

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire